ScholarIQanswers from OpenAlex & ORCID
Subrata Ghosh
ResearcherPublications, citations & collaboration network
Subrata Ghosh is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Subrata Ghosh have?
ScholarIQindexed works
Subrata Ghosh has 1,025 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Subrata Ghosh have?
ScholarIQcitation count
Subrata Ghosh has 47,372 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Subrata Ghosh?
ScholarIQh-index
Subrata Ghosh has an h-index of 97 in OpenAlex.
What is the i10-index of Subrata Ghosh?
ScholarIQi10-index
Subrata Ghosh has an i10-index of 399 in OpenAlex.
What is the ORCID of Subrata Ghosh?
ScholarIQorcid
The ORCID for Subrata Ghosh is on the source record.
What is the OpenAlex record for Subrata Ghosh?
ScholarIQopenalex
The OpenAlex for Subrata Ghosh is on the source record.
What are the most-cited papers on Subrata Ghosh?
ScholarIQmost cited works
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng, Hai Yun Shi, Nima Hamidi, Fox E. Underwood, Whitney Tang, Eric I. Benchimol, Remo Panaccione, Subrata Ghosh, Justin C. Wu, Francis K.L. Chan, Joseph J.�Y. Sung, Gilaad G. Kaplan
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan, William J. Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R. Friedman, Marion Blank, Jewel Johanns, Long-Long Gao, Miao Ye, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B. Hanauer, Séverine Vermeire, Stephan R. Targan, Subrata Ghosh, Willem J. de Villiers, Jean–Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce Salzberg, Pierre Desreumaux, Scott D. Lee, Edward V. Loftus, Levinus A. Dieleman, Seymour Katz, Paul Rutgeerts
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis
Ren Mao, Yun Qiu, Jin-Shen He, Jin-Yu Tan, Xue-hua Li, Jie Liang, Jun Shen, Liang-Ru Zhu, Yan Chen, Marietta Iacucci, Siew C. Ng, Subrata Ghosh, Minhu Chen
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
William J. Sandborn, William J. Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranić, Wenjin Wang, Wojciech Niezychowski, Séverine Vermeire, Olivier Dewit, Harald Peeters, Jiřı́ Stehlı́k, Tomáš Vaňásek, David Laharie, Jean Frédéric Colombel, M A Bigard, Márta Varga, Margit Zeher, János Novák, Béla Hunyady, Á Salamon, I Rácz, Paolo Gionchetti, Anna Kohn, Cosimo Prantera, Pieter Stokkers, Maria Słomka, Leszek Paradowski, Tomasz Arłukowicz, L Kuzela, Boris Baricky, Tibor Hlavatý, María Isabel Vera-Muñoz, Julian Panes, Jordi Guardiola, C Probert, JL Shaffer, Mark Fleisher, Ronald Edward Pruitt, William J. Sandborn, William J. Sandborn, John S. Goff, John T. Weber, R. Bell, Andrew Zwick, Alexandra Gutierrez, Robert H. Levine, Stephen Brett Hanauer, Lori Ann Lavelle, Ravindranath Kottoor, Gerald Wayne Dryden, Robert Hardi, David Vaughn Glorioso, Prabhakar Swaroop, Scott D. Lee, Teressa Joan Patrick, Sheldon Scheinert, Charles A. Sninsky, Seymour Katz, Mark D. Noar, Marco Gaspari, Glenn L. Gordon, Thomas A. Dalton, Douglas Edward Homoky, William Ransom Kilgore, Joel A. Levien, Herbert R. Schneider, S. Moola, Frederik Cornelius Kruger, John Wright, Nazimuddin Aboo
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M. Davis, Stephen B. Hanauer, Brian G. Feagan, Subrata Ghosh, William J. Sandborn